Clinical trials of Central Nervous System (CNS) disorders have some of the most challenging clinical outcome assessments in all of drug development.
Study teams face a myriad of issues that can diminish the ability to detect drug-related changes such as rater reliability, administration and scoring errors, cultural equivalence, placebo effects, and practice effects.
Cogstate has 20 years of experience developing and applying pioneering digital technologies with leading neuroscience and operational expertise to reduce the risk, burden, and delay that can detrimentally impact CNS study results.
Key Therapeutic Focus Areas
Our team of scientific and operational experts have supported study outcomes in 60+ indications across neurology, rare diseases, mood disorders, oncology, movement disorders, and infectious disease. Learn more about our unique capabilities in a selection of key focus areas:
Alzheimer’s Disease
Rare Disease
Multiple Sclerosis
Parkinson’s Disease
Schizophrenia
Oncology
Safety
And Many More
Solutions for Every Stage of Your Study Development
Our team supports both digital and conventional assessments of cognition, behavior, development and symptom severity for a wide range of study objectives and indications, delivering proven solutions to help you optimize signal detection.
Scientific Consulting
Digital Cognitive Assessment
Rater Training
Central Monitoring
Scale Management
